A
Alan Horwich
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 368
Citations - 32077
Alan Horwich is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Seminoma & Prostate cancer. The author has an hindex of 88, co-authored 366 publications receiving 29943 citations. Previous affiliations of Alan Horwich include University of Toronto & Cheltenham General Hospital.
Papers
More filters
Journal ArticleDOI
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard Escudier,Camillo Porta,Manuela Schmidinger,Nathalie Rioux-Leclercq,Axel Bex,Vincent Khoo,Vincent Khoo,V. Gruenvald,Alan Horwich +8 more
TL;DR: RCC appears to be more common in patients with obesity, end-stage renal failure, acquired renal cystic disease and tuber-ous sclerosis, and severalautosomal dominant syndromes are described, each with a dis-tinct genetic basis and phenotype.
Journal ArticleDOI
Carboplatin or cisplatin
A.H. Calvert,Alan Horwich,Edward S. Newlands,R. H. J. Begent,Gordon J. S. Rustin,Stan B. Kaye,A.L. Harris,C. J. Williams,Maurice L. Slevin +8 more
Journal Article
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
Graham M. Mead,S. P. Stenning,P. A. Cook,Sophie D. Fosså,Alan Horwich,Stan B. Kaye,R.T.D. Oliver,Phm deMulder,R deWit,Gerrit Stoter,Richard Sylvester,Dean F. Bajorin,George J. Bosl,M Mazumdar,Craig R. Nichols,Robert J. Amato,Giorgio Pizzocaro,Jean-Pierre Droz,Andrew Kramar,Gedske Daugaard,H. Cortes-Funes,Luis Paz-Ares,John A. Levi,B. M. Colls,V J Harvey,C Coppin +25 more
TL;DR: An easily applicable, clinically based, prognostic classification for GCT has been agreed on between all the major clinical trial groups who are presently active worldwide and should be used in clinical practice and in the design and reporting of clinical trials to aid international collaboration and understanding.
Journal ArticleDOI
Multiple newly identified loci associated with prostate cancer susceptibility.
Rosalind A. Eeles,Rosalind A. Eeles,Zsofia Kote-Jarai,Graham G. Giles,Graham G. Giles,Ali Amin Al Olama,Michelle Guy,Sarah Jugurnauth,Shani Mulholland,Daniel Leongamornlert,Stephen M. Edwards,Jonathan J. Morrison,Helen I. Field,Melissa C. Southey,Gianluca Severi,Gianluca Severi,Jenny L Donovan,Freddie C. Hamdy,David P. Dearnaley,David P. Dearnaley,Kenneth Muir,Charmaine Smith,Melisa Bagnato,Audrey Ardern-Jones,Amanda L. Hall,Amanda L. Hall,Lynne T. O'Brien,Beatrice N. Gehr-Swain,Beatrice N. Gehr-Swain,Rosemary A. Wilkinson,Cox A,Sarah J Lewis,Paul M. Brown,Sameer Jhavar,Malgorzata Tymrakiewicz,Artitaya Lophatananon,Sarah L Bryant,Alan Horwich,Alan Horwich,Robert Huddart,Robert Huddart,Vincent Khoo,Vincent Khoo,Chris Parker,Chris Parker,C. R. J. Woodhouse,Alan Thompson,Tim Christmas,Chris Ogden,Cyril Fisher,Charles Jamieson,Colin Cooper,Dallas R. English,John L. Hopper,David E. Neal,Douglas F. Easton +55 more
TL;DR: A genome-wide association study using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at ≤60 years or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml) identified seven loci associated with prostate cancer on chromosomes 3, 6, 7, 10, 11, 19 and X.
Journal ArticleDOI
Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial
David P. Dearnaley,Vincent Khoo,Andrew R. Norman,Lesley Meyer,Alan E. Nahum,Diana Tait,John Yarnold,Alan Horwich +7 more
TL;DR: Conformal techniques significantly lowered the risk of late radiation-induced proctitis after radiotherapy for prostate cancer, and are the basis for dose-escalation studies to improve local tumour control.